The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review

Publication date: June 2018
Source:Biomedicine & Pharmacotherapy, Volume 102
Author(s): Dinesh Kumar Chellappan, Kun Hooi Leng, Lee Jia Jia, Nur Amirah Binti Abdul Aziz, Wong Chun Hoong, Yap Cheng Qian, Fam Yi Ling, Gwee Sing Wei, Tiong Ying, Jestin Chellian, Gaurav Gupta, Kamal Dua
ObjectiveThe study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers.MethodsThe study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies. Studies related with the trials of angiogenesis and bevacizumab were selected in the review.ResultsIn general, the management of gynecological cancers include chemotherapy, surgery and radiation therapy. Results suggest bevacizumab as an effective treatment modality for cervical and several other cancers. Overall, bevacizumab showed promising results in improving the overall survival rate of gynecological cancer patients through the combination of bevacizumab with other chemotherapeutic agents.ConclusionBevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.



https://ift.tt/2IuAf5y